(MedPage Today) — A single infusion of adeno-associated virus (AAV)-mediated gene therapy led to sustained clinical benefit and no late-onset safety concerns in patients with severe hemophilia B, a longitudinal study showed.
At a median follow…
Source link : https://www.medpagetoday.com/hematologyoncology/hemophilia/116033
Author :
Publish date : 2025-06-12 15:19:00
Copyright for syndicated content belongs to the linked Source.
